• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Neuronetics Inc.

    6/2/25 4:31:33 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SD 1 d945937dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    SPECIALIZED DISCLOSURE REPORT

     

     

    NEURONETICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38546

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    file number)

    3222 Phoenixville Pike

    Malvern, PA

      19355
    (Address of principal executive offices)   (Zip Code)

    W. Andrew Macan

    (610) 640-4202

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2024.

     

     
     


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    In accordance with the disclosure requirements promulgated by the U.S. Securities and Exchange Commission, Neuronetics, Inc. (the “Company”) has undertaken efforts to determine its conflict minerals1 reporting requirements for the period from January 1 to December 31, 2024.

    The Company has filed this Specialized Disclosure Report and the associated Conflict Minerals Report, which appears as Exhibit 1.01 hereto and is publicly available through the Company’s website at ir.neuronetics.com/corporate-governance/highlights.

    Item 1.02 Exhibit

    The Company has filed as an Exhibit to this Form SD its Conflict Minerals Report for calendar year ended December 31, 2024.

     
    1 

    The term “conflict mineral” is defined in Section 1502(e)(4) of the Dodd-Frank Wall Street Reform and Consumer Protection Act as (A) columbite-tantalite, also known as coltan (the metal ore from which tantalum is extracted); cassiterite (the metal ore from which tin is extracted); gold; wolframite (the metal ore from which tungsten is extracted); or their derivatives; or (B) any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of the Congo or an adjoining country.


    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

    Item 3.01 Exhibits

    The following exhibit is filed as part of this report.

    Exhibit 1.01 – Neuronetics, Inc.’s Conflict Minerals Report for the reporting period from January 1 to December 31, 2024.

    *****


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Neuronetics, Inc.    
    By:  

    /s/ W. Andrew Macan

      Date: June 2, 2025  
      W. Andrew Macan    
      Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary    
    Get the next $STIM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    SEC Filings

    View All

    SEC Form 144 filed by Neuronetics Inc.

    144 - Neuronetics, Inc. (0001227636) (Subject)

    8/8/25 4:54:08 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Neuronetics Inc.

    424B5 - Neuronetics, Inc. (0001227636) (Filer)

    8/6/25 4:30:21 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Neuronetics Inc.

    10-Q - Neuronetics, Inc. (0001227636) (Filer)

    8/5/25 7:31:19 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards

    8/6/25 4:45:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Reports Second Quarter 2025 Financial and Operating Results

    Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need he

    8/5/25 7:05:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

    MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following th

    8/4/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Madryn Asset Management, Lp sold $13,020,000 worth of shares (3,500,000 units at $3.72) (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/12/25 4:15:10 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pfanstiel Steven

    3 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    EVP, CFO and Treasurer Pfanstiel Steven was granted 400,000 shares (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/25 5:00:04 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    10/13/21 12:25:53 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/6/24 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/30/24 5:15:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

    6/2/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    7/12/23 9:00:00 AM ET
    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d6qidqaw. To listen to the conference call on your telephone, participants may register for t

    7/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

    4/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

    2/21/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care